Laurion Capital Management LP has recently announced that it has increased stake in BridgeBio Pharma Inc (NASDAQ:BBIO) by 18.99%. After grabbing 5.65 million shares, the institutional investor is now in possession of 0.9 million shares of the Healthcare Company. The new investment brought the stake of investor firm to 3.25% having worth around $162.24 million. Moreover, Cormorant Asset Management LP increased its share by 0.49 million to have a control over 4.66 million shares. And Pictet Asset Management SA raised its holdings to 2.74 million shares by acquiring 2.74 million shares or 1.58% of the stake.
BridgeBio Pharma Inc (BBIO) concluded trading on 01/04/24 at a closing price of $36.92, with 3.05 million shares of worth about $112.48 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 117.18% during that period and on Thursday the price saw a loss of about -2.46%. Currently the company’s common shares owned by public are about 150.63M shares, out of which, 128.29M shares are available for trading.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 41 times over the past 12 months. They bought 408,212 shares in 11 of the transactions. In 30 selling transactions, insiders dumped 2,806,877 shares.
Vanguard Total Stock Market ETF, Vanguard Small Cap Index Fund, and iShares Russell 2000 ETF are the top 3 mutual funds which are holding stakes in BridgeBio Pharma Inc Vanguard Total Stock Market ETF is currently holding 3.57 million shares of worth totaling $102.59 million. The company recently came buying 4956.0 shares which brought its stake up to 2.05% of the company’s outstanding shares. Vanguard Small Cap Index Fund bought 9035.0 shares, after which its hold over company’s outstanding shares expand to 1.69%, leaving 2.94 million shares with the mutual fund that have a worth of about $84.51 million. iShares Russell 2000 ETF, after buying 2.78 million shares, have now control over 1.60% of the stake in the company. It holds 1365.0 shares of worth $79.75 million.
BridgeBio Pharma Inc (NASDAQ: BBIO) started trading at $38.02, above $0.17 from concluding price of the previous day. However, the stock later moved at a day high price of 38.34, or with a loss of -2.46%. Stock saw a price change of -15.88% in past 5 days and over the past one month there was a price change of 15.59%. Year-to-date (YTD), BBIO shares are showing a performance of -8.55% which increased to 414.92% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $7.14 but also hit the highest price of $44.32 during that period. The average intraday trading volume for BridgeBio Pharma Inc shares is 1.53 million. The stock is currently trading -1.55% below its 20-day simple moving average (SMA20), while that difference is up 16.25% for SMA50 and it goes to 52.55% higher than SMA200.
Laurion Capital Management LP acquired 5.65 million shares of BridgeBio Pharma Inc having value of about $162.24 million. Data submitted at the U.S SEC by Laurion Capital Management LP revealed that the firm now holds 0.9 million shares in the company valued at close to $33290616.32, or have control over 18.99% stake in the company. BridgeBio Pharma Inc (NASDAQ: BBIO) currently have 150.63M outstanding shares and institutions hold larger chunk of about 73.51% of that. Holding of mutual funds in the company is about 49.46% while other institutional holders and individual stake holders have control over 59.62% and 24.04% of the stake respectively.
The stock has a current market capitalization of $6.42B and its 3Y-monthly beta is at 1.08. It has posted earnings per share of -$3.91 in the same period. It has Quick Ratio of 5.54. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for BBIO, volatility over the week remained 5.30% while standing at 5.56% over the month.
Analysts are in expectations that BridgeBio Pharma Inc (BBIO) stock would likely to be making an EPS of -$0.92 in the current quarter, while forecast for next quarter EPS is -$0.95 and it is -$3.54 for next year. For the current quarter EPS, analysts have given the company a lowest target -$1.16 which is -$0.64 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$0.92 in the same quarter a year ago. Stock’s fiscal year EPS is expected to drop by -15.66% while it is estimated to increase by 10.42% in next year.
Analysts at 12 brokerage firms have issued recommendations for the BridgeBio Pharma Inc (BBIO)’s stock and average of those rates the stock at a “Strong Buy” and assign it a score of 1.17. Out of those 12 Wall Street analysts, 11 recommended a “Buy” rating, while 1 were in favor recommending the stock as a “Hold” and 0 analyst recommended the stock as “Sell”.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Wells Fargo on December 08, 2023 offering an Overweight rating for the stock and assigned a target price of $58 to it.
